HDAC inhibitor Vorinostat was shown to reduce levels of BRCA1-associated RING domain 1 (BARD1) by increasing the expression of miR-19a/b in AML [157] (Table 4). This evidence concerns the gene BARD1 and acute myeloid leukemia.